These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30504510)

  • 1. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
    Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
    J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
    Rech J; Hueber AJ; Finzel S; Englbrecht M; Haschka J; Manger B; Kleyer A; Reiser M; Cobra JF; Figueiredo C; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Schett G
    Ann Rheum Dis; 2016 Sep; 75(9):1637-44. PubMed ID: 26483255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.
    Boeters DM; Burgers LE; Sasso EH; Huizinga TWJ; van der Helm-van Mil AHM
    Arthritis Res Ther; 2019 May; 21(1):121. PubMed ID: 31088574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
    Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
    Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
    de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
    Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
    Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
    Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
    Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
    J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
    Burgers LE; Boeters DM; Reijnierse M; van der Helm-van Mil AHM
    Arthritis Res Ther; 2018 Apr; 20(1):68. PubMed ID: 29636084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
    Verstappen M; van Steenbergen HW; de Jong PHP; van der Helm-van Mil AHM
    Arthritis Res Ther; 2022 Jan; 24(1):4. PubMed ID: 34980246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
    El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
    Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.
    Moysidou GS; Marotte H; Kossi S; Tubach F; Hajage D; Fautrel B
    Clin Exp Rheumatol; 2023 Sep; 41(9):1831-1837. PubMed ID: 37497730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
    Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
    Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
    Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.
    Burgers LE; van der Pol JA; Huizinga TWJ; Allaart CF; van der Helm-van Mil AHM
    Arthritis Res Ther; 2019 May; 21(1):115. PubMed ID: 31064384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.
    Ghiti Moghadam M; Lamers-Karnebeek FBG; Vonkeman HE; Ten Klooster PM; Tekstra J; Schilder AM; Visser H; Sasso EH; Chernoff D; Lems WF; van Schaardenburg DJ; Landewe R; Bernelot Moens HJ; Radstake TRDJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    PLoS One; 2018; 13(5):e0192425. PubMed ID: 29791439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
    Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
    Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.